Victory Capital Management Inc. Has $568,000 Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Victory Capital Management Inc. increased its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 1,091.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,138 shares of the company’s stock after buying an additional 111,889 shares during the period. Victory Capital Management Inc.’s holdings in GoodRx were worth $568,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Versor Investments LP acquired a new position in GoodRx during the 4th quarter valued at about $54,000. Verus Capital Partners LLC acquired a new position in GoodRx during the 4th quarter valued at about $55,000. Steward Partners Investment Advisory LLC acquired a new position in GoodRx during the 4th quarter valued at about $56,000. EP Wealth Advisors LLC bought a new stake in shares of GoodRx in the 3rd quarter valued at about $73,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of GoodRx in the 3rd quarter valued at about $85,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Stock Performance

Shares of GDRX stock opened at $4.64 on Friday. The business’s 50-day moving average price is $4.75 and its 200-day moving average price is $5.43. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -154.67, a PEG ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GDRX shares. KeyCorp lowered their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Citigroup lowered their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Morgan Stanley lowered their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Wells Fargo & Company lowered their price target on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, Mizuho initiated coverage on GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.18.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.